it should be mildly bullish but the company still likely won't develop this without a partner, the details of the ensitrelvir data are not yet public they are saving it for a scientific presentation, and the regulatory pathway in this indication has yet to be hammered out. But yes there now does seem to be potential for a new path to market which you would think is a positive for resurrecting some discussion with partners on 235. There could be a delayed reaction who knows there was nothing on the news wires when I first posted the info, but this is enta we are talking about so it is always hard to explain away the day to day trading
Market Data 
Markets 
AI
